The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.

The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.

BACKGROUND:The discussion on the use of bevacizumab is still ongoing and often doctors are deterred from using bevacizumab due to legal or political issues. Bevacizumab is an effective, safe and inexpensive treatment option for neovascular age-related macular degeneration (AMD), albeit unregistered...

Full description

Bibliographic Details
Main Authors: Freekje van Asten, Charlotte T J Michels, Carel B Hoyng, Gert Jan van der Wilt, B Jeroen Klevering, Maroeska M Rovers, Janneke P C Grutters
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5957378?pdf=render

Internet

http://europepmc.org/articles/PMC5957378?pdf=render

Similar Items